Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Global trial of PTG-300 in patients with myelodysplastic syndrome (MDS)

Next Previous
Trial Profile

Global trial of PTG-300 in patients with myelodysplastic syndrome (MDS)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rusfertide (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use

    • Most Recent Events

    • 11 Oct 2021 According to a Protagonist Therapeutics media release, the company announced that the U.S. Food and Drug Administration (FDA) has removed the full clinical hold on the Companys rusfertide clinical studies. Per the FDA, dosing in all clinical studies of rusfertide may be resumed. The Company is working closely with study investigators and clinical trial sites to resume dosing of patients in ongoing clinical trials with rusfertide after patients have been reconsented.
    • 17 Sep 2021 According to a Protagonist Therapeutics media release, the U.S. FDA have placed a clinical hold on clinical studies of rusfertide after a non-clinical finding in a 26-week rasH2 transgenic mouse model study, benign and malignant subcutaneous skin tumors were observed in the study. The dosing of patients in all ongoing clinical trials with rusfertide will be put on hold, and study investigators have been contacted to facilitate patient notification.
    • 10 Mar 2020 According to a Protagonist Therapeutics media release, the company expects to initiate this trial in the first half of 2020.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top